title: Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
abstract: OBJECTIVE
  We carried out a systematic review and meta-analysis to assess the efficacy and safety of imidafenacin for treating overactive bladder in adult.
  
  
  METHODS
  A literature review was performed to identify all published randomized placebo-controlled trials of imidafenacin for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE. The reference lists of retrieved studies were also investigated.
  
  
  RESULTS
  Five publications involving a total of 1,428 patients were used in the analysis, which compared imidafenacin with propiverine and solifenacin. We found that imidafenacin was effective in treating OAB in our meta-analysis, which was similar to propiverine in its efficacy. The mean number of UI per week (the standardized mean difference (SMD) = 1.23, 95% CI -0.19 to 2.65, p = 0.09), the mean number of urgency episodes per day (SMD = 0.26, 95% CI -0.11 to 0.63, p = 0.17), the mean number of micturitions per day (SMD = 0.01, 95% CI -0.30 to 0.31, p = 0.96), and the mean urine volume (ml) per micturition (SMD = -13.04, 95% CI -20.45 to -5.62, p = 0.0006) indicated that imidafenacin was similar to propiverine in its efficacy. Mean OABSS (SMD = 0.48, 95% CI -0.08 to 1.03, p = 0.09) indicated that imidafenacin was also similar to solifenacin in its efficacy. Besides, imidafenacin was better tolerated than propiverine in the safety, indicated by dry mouth (OR 0.73, 95% CI 0.54-0.98, p = 0.04) and any adverse events (OR 0.63, 95% CI 0.46-0.88, p = 0.006). Moreover, imidafenacin was also better tolerated than solifenacin in the safety, indicated by constipation (OR 0.21, 95% CI 0.08-0.53, p = 0.001) and any adverse events (OR 0.33, 95% CI 0.15-0.71, p = 0.004).
  
  
  CONCLUSIONS
  This meta-analysis indicates that imidafenacin was similar to propiverine or solifenacin in its efficacy for OAB and was better tolerated than propiverine or solifenacin in the safety for OAB. We conclude that imidafenacin is preferable to propiverine or solifenacin from a perspective of safety.
authors: Urology Department, Beijing Tian Tan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dong cheng District, Beijing, 100050, China.
authors: Wei
authors: W
authors: Huang
authors: Huantao
authors: H
authors: Zong
authors: Xin
authors: X
authors: Zhou
authors: Yong
authors: Y
authors: Zhang
mesh_terms: D000328:Adult; D001561:Benzilates / Q000627:therapeutic use; D003248:Constipation / Q000139:chemically induced; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069464:Solifenacin Succinate / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
chemical_list: D001561:Benzilates; D007093:Imidazoles; D064804:Urological Agents; C015586:propiverine; D000069464:Solifenacin Succinate; C120953:imidafenacin
references: Curr Opin Urol. 2009 Jul;19(4):380-94
references: 19448545
references: Urol Int. 2003;71(3):290-8
references: 14512651
references: World J Urol. 2003 May;20(6):327-36
references: 12811491
references: Neurourol Urodyn. 2002;21(2):167-78
references: 11857671
references: Int J Clin Pract. 2011 May;65(5):567-85
references: 21489081
references: BMJ. 2012 Apr 17;344:e2365
references: 22511208
references: Int J Urol. 2008 Oct;15(11):986-91
references: 18761536
references: Urol Int. 2013;90(2):161-7
references: 23207959
references: BJU Int. 1999 Apr;83(6):583-90
references: 10233562
references: BJU Int. 2001 Jun;87(9):760-6
references: 11412210
references: Int J Urol. 2008 Sep;15(9):809-15
references: 18637156
references: Int J Clin Pract. 2014 Feb;68(2):188-96
references: 24373019
references: Int J Urol. 2009 May;16(5):499-506
references: 19389083
references: Pharmacoeconomics. 2005;23(10):995-1006
references: 16235973
references: Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90
references: 11183901
references: Urology. 2000 May;55(5A Suppl):33-46; discussion 50
references: 10767450
references: Adv Urol. 2011;2011:854697
references: 22046182
references: Urol Int. 2012;89(2):215-21
references: 22832092
references: Arzneimittelforschung. 2007;57(2):92-100
references: 17396619
references: Arzneimittelforschung. 2007;57(3):147-54
references: 17469649